Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

In vitro immunotherapy potency assays using real-time cell analysis.

Cerignoli F, Abassi YA, Lamarche BJ, Guenther G, Santa Ana D, Guimet D, Zhang W, Zhang J, Xi B.

PLoS One. 2018 Mar 2;13(3):e0193498. doi: 10.1371/journal.pone.0193498. eCollection 2018.

2.

An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes.

McKeithan WL, Savchenko A, Yu MS, Cerignoli F, Bruyneel AAN, Price JH, Colas AR, Miller EW, Cashman JR, Mercola M.

Front Physiol. 2017 Oct 11;8:766. doi: 10.3389/fphys.2017.00766. eCollection 2017.

3.

High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.

Del Álamo JC, Lemons D, Serrano R, Savchenko A, Cerignoli F, Bodmer R, Mercola M.

Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1717-27. doi: 10.1016/j.bbamcr.2016.03.003. Epub 2016 Mar 4. Review.

4.

High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds.

Lu HR, Whittaker R, Price JH, Vega R, Pfeiffer ER, Cerignoli F, Towart R, Gallacher DJ.

Toxicol Sci. 2015 Dec;148(2):503-16. doi: 10.1093/toxsci/kfv201. Epub 2015 Sep 9.

PMID:
26358003
5.

DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase.

Amand M, Erpicum C, Bajou K, Cerignoli F, Blacher S, Martin M, Dequiedt F, Drion P, Singh P, Zurashvili T, Vandereyken M, Musumeci L, Mustelin T, Moutschen M, Gilles C, Noel A, Rahmouni S.

Mol Cancer. 2014 May 15;13:108. doi: 10.1186/1476-4598-13-108.

6.

High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry.

Cerignoli F, Charlot D, Whittaker R, Ingermanson R, Gehalot P, Savchenko A, Gallacher DJ, Towart R, Price JH, McDonough PM, Mercola M.

J Pharmacol Toxicol Methods. 2012 Nov-Dec;66(3):246-56. doi: 10.1016/j.vascn.2012.08.167. Epub 2012 Aug 25.

7.

Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells.

Wu S, Vossius S, Rahmouni S, Miletic AV, Vang T, Vazquez-Rodriguez J, Cerignoli F, Arimura Y, Williams S, Hayes T, Moutschen M, Vasile S, Pellecchia M, Mustelin T, Tautz L.

J Med Chem. 2009 Nov 12;52(21):6716-23. doi: 10.1021/jm901016k. Erratum in: J Med Chem. 2009 Dec 24;52(24):8058.

8.

Notch activates cell cycle reentry and progression in quiescent cardiomyocytes.

Campa VM, Gutiérrez-Lanza R, Cerignoli F, Díaz-Trelles R, Nelson B, Tsuji T, Barcova M, Jiang W, Mercola M.

J Cell Biol. 2008 Oct 6;183(1):129-41. doi: 10.1083/jcb.200806104.

9.

Cell-type specific and cytoplasmic targeting of PEGylated carbon nanotube-based nanoassemblies.

Cato MH, D'Annibale F, Mills DM, Cerignoli F, Dawson MI, Bergamaschi E, Bottini N, Magrini A, Bergamaschi A, Rosato N, Rickert RC, Mustelin T, Bottini M.

J Nanosci Nanotechnol. 2008 May;8(5):2259-69.

PMID:
18572636
10.

Cutting edge: selective tyrosine dephosphorylation of interferon-activated nuclear STAT5 by the VHR phosphatase.

Hoyt R, Zhu W, Cerignoli F, Alonso A, Mustelin T, David M.

J Immunol. 2007 Sep 15;179(6):3402-6.

11.

Quantum dot-doped silica nanoparticles as probes for targeting of T-lymphocytes.

Bottini M, D'Annibale F, Magrini A, Cerignoli F, Arimura Y, Dawson MI, Bergamaschi E, Rosato N, Bergamaschi A, Mustelin T.

Int J Nanomedicine. 2007;2(2):227-33.

12.

SKAP55 modulates T cell antigen receptor-induced activation of the Ras-Erk-AP1 pathway by binding RasGRP1.

Kosco KA, Cerignoli F, Williams S, Abraham RT, Mustelin T.

Mol Immunol. 2008 Jan;45(2):510-22. Epub 2007 Jul 20.

PMID:
17658605
13.

Luminescent silica nanobeads: characterization and evaluation as efficient cytoplasmatic transporters for T-lymphocytes.

Bottini M, Cerignoli F, Mills DM, D'Annibale F, Leone M, Rosato N, Magrini A, Pellecchia M, Bergamaschi A, Mustelin T.

J Am Chem Soc. 2007 Jun 27;129(25):7814-23. Epub 2007 Jun 2.

14.

Identification and characterization of DUSP27, a novel dual-specific protein phosphatase.

Friedberg I, Nika K, Tautz L, Saito K, Cerignoli F, Friedberg I, Godzik A, Mustelin T.

FEBS Lett. 2007 May 29;581(13):2527-33. Epub 2007 Apr 30.

15.

Adsorption of streptavidin onto single-walled carbon nanotubes: application in fluorescent supramolecular nanoassemblies.

Bottini M, Cerignoli F, Tautz L, Rosato N, Bergamaschi A, Mustelin T.

J Nanosci Nanotechnol. 2006 Dec;6(12):3693-8.

PMID:
17256317
16.

Regulation of MAP kinases by the VHR dual-specific phosphatase: implications for cell growth and differentiation.

Cerignoli F, Rahmouni S, Ronai Z, Mustelin T.

Cell Cycle. 2006 Oct;5(19):2210-5. Epub 2006 Oct 1. Review.

PMID:
17012840
17.

Full-length single-walled carbon nanotubes decorated with streptavidin-conjugated quantum dots as multivalent intracellular fluorescent nanoprobes.

Bottini M, Cerignoli F, Dawson MI, Magrini A, Rosato N, Mustelin T.

Biomacromolecules. 2006 Aug;7(8):2259-63.

PMID:
16903668
18.

Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence.

Rahmouni S, Cerignoli F, Alonso A, Tsutji T, Henkens R, Zhu C, Louis-dit-Sully C, Moutschen M, Jiang W, Mustelin T.

Nat Cell Biol. 2006 May;8(5):524-31. Epub 2006 Apr 9. Erratum in: Nat Cell Biol. 2006 Jun;8(6):642.

PMID:
16604064
19.

High mobility group A1 is a molecular target for MYCN in human neuroblastoma.

Giannini G, Cerignoli F, Mellone M, Massimi I, Ambrosi C, Rinaldi C, Dominici C, Frati L, Screpanti I, Gulino A.

Cancer Res. 2005 Sep 15;65(18):8308-16.

20.

Molecular mechanism of HMGA1 deregulation in human neuroblastoma.

Giannini G, Cerignoli F, Mellone M, Massimi I, Ambrosi C, Rinaldi C, Gulino A.

Cancer Lett. 2005 Oct 18;228(1-2):97-104. Review.

PMID:
15923078
21.

HMGA molecules in neuroblastic tumors.

Cerignoli F, Ambrosi C, Mellone M, Assimi I, di Marcotullio L, Gulino A, Giannini G.

Ann N Y Acad Sci. 2004 Dec;1028:122-32. Review.

PMID:
15650238
22.

Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability.

Giannini G, Rinaldi C, Ristori E, Ambrosini MI, Cerignoli F, Viel A, Bidoli E, Berni S, D'Amati G, Scambia G, Frati L, Screpanti I, Gulino A.

Oncogene. 2004 Apr 8;23(15):2640-7.

PMID:
15048091
23.

EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer.

Giannini G, Ambrosini MI, Di Marcotullio L, Cerignoli F, Zani M, MacKay AR, Screpanti I, Frati L, Gulino A.

Mol Carcinog. 2003 Dec;38(4):188-200.

PMID:
14639658
24.

retSDR1, a short-chain retinol dehydrogenase/reductase, is retinoic acid-inducible and frequently deleted in human neuroblastoma cell lines.

Cerignoli F, Guo X, Cardinali B, Rinaldi C, Casaletto J, Frati L, Screpanti I, Gudas LJ, Gulino A, Thiele CJ, Giannini G.

Cancer Res. 2002 Feb 15;62(4):1196-204.

25.

Human MRE11 is inactivated in mismatch repair-deficient cancers.

Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, Ottini L, Crescenzi M, Martinotti S, Bignami M, Frati L, Screpanti I, Gulino A.

EMBO Rep. 2002 Mar;3(3):248-54. Epub 2002 Feb 15.

26.

Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status.

Giannini G, Kim CJ, Di Marcotullio L, Manfioletti G, Cardinali B, Cerignoli F, Ristori E, Zani M, Frati L, Screpanti I, Guilino A.

Br J Cancer. 2000 Dec;83(11):1503-9.

27.

Increased expression of c-fos, c-jun and LRF-1 is not required for in vivo priming of hepatocytes by the mitogen TCPOBOP.

Columbano A, Ledda-Columbano GM, Pibiri M, Piga R, Shinozuka H, De Luca V, Cerignoli F, Tripodi M.

Oncogene. 1997 Feb 20;14(7):857-63.

Supplemental Content

Loading ...
Support Center